Alzheimer's disease

Todos Medical Reports Second Quarter 2021 Financial Results

Friday, September 24, 2021 - 2:36pm

New York, NY, and Tel Aviv, ISRAEL, Sept. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results today for the second quarter of 2021 ended June 30, 2021. 

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Sept. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (Todos Medical) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results todayfor the second quarter of 2021 endedJune 30, 2021.
  • Revenues: Total revenue in the second quarter of 2021 was$1.7 million, a significant increase compared to revenue of $32,000in the second quarter of 2020.
  • Loss from Operations: The Company recorded an operating loss of$(1,662,0000)in the second quarter of 2021 compared to an operating loss of$(1.719,000)in the second quarter of 2020.
  • "While we achieved significant business milestones in the second quarter, we also witnessed several key improvements to our financial condition as well," saidDaniel Hirsch, CFO of Todos Medical.

UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders

Friday, September 24, 2021 - 2:01pm

We are very pleased to have received the support from our existing convertible note holders with this lockup agreement, said Gerald E. Commissiong, President & CEO.

Key Points: 
  • We are very pleased to have received the support from our existing convertible note holders with this lockup agreement, said Gerald E. Commissiong, President & CEO.
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.
  • Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States.

Telo Genomics Announces Full-Services Investor Relations Agreement with Adelaide Capital

Tuesday, September 21, 2021 - 1:45pm

Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has entered into a consulting agreement (the "Consulting Agreement") with Adelaide Capital Markets Inc. ("Adelaide") to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the "TSXV") and applicable legislation.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has entered into a consulting agreement (the "Consulting Agreement") with Adelaide Capital Markets Inc. ("Adelaide") to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the "TSXV") and applicable legislation.
  • Adelaide will provide investor relations and consulting services to the Company, effective September 15, 2021.
  • Under the terms of the Consulting Agreement, Adelaide will receive C$8,000 per month from the Company for an initial period of 6 months (subject to extension by mutual agreement) until March 15, 2022.
  • Adelaide will, among other things, assist with investor introductions and communications, respond to investor and shareholder inquires, work with TELO to prepare corporate materials and press releases and coordinate non-deal roadshows, virtual campaigns, and conferences.

Alpha Cognition Announces Pricing of Public Offering

Thursday, September 23, 2021 - 3:18pm

VANCOUVER, British Columbia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that, in connection with its previously announced overnight marketed offering, a syndicate of agents led by Raymond James Ltd. and including iA Private Wealth Inc. (collectively, the "Agents"), have agreed to sell 8,350,000 units ("Units") of the Company at a price of $1.50 per Unit (the "Issue Price") for aggregate gross proceeds of approximately $12.5 million (the "Offering"). Each Unit will consist of one common share in the capital of Alpha (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $1.75 for a period of 24 months from the closing date of the Offering.

Key Points: 
  • Each Unit will consist of one common share in the capital of Alpha (a Common Share) and one common share purchase warrant (a Warrant).
  • The Offering is being conducted pursuant to the Companys Canadian base shelf prospectus dated August 25, 2021 (the Base Shelf Prospectus).
  • A prospectus supplement (the Prospectus Supplement) relating to the Offering will be filed in each of the provinces of Canada, except Quebec.
  • Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).

Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com

Thursday, September 23, 2021 - 1:37pm

New York, NY, and Tel Aviv, ISRAEL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced an expansion of its Tollovid® dietary supplement 3CL protease (MPro) inhibitor immune support product line with the launch of Tollovid Daily™ via subscription. The subscription model takes the hassle out of remembering to order Tollovid Daily on a monthly basis. 

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (Todos Medical) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced an expansion of its Tollovid dietary supplement 3CL protease (MPro) inhibitor immune support product line with the launch of Tollovid Daily via subscription .
  • Both Tollovid and Tollovid Daily are 3CL protease inhibitors for immune support that have 60 caplets per bottle.
  • Tollovid Daily was designed as a twice-daily dosing schedule for people on the go that provides one month of daily immune support.
  • Tollovid Daily is an affordable immune support solutionwith mass market appeal, said Gerald Commission CEO of Todos Medical.

BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO "Dr. Louis St. L. O'Dea" as CMO of BIORCHESTRA

Thursday, September 23, 2021 - 1:00pm

In addition, their proprietary exosome-based diagnostic that detects and quantifies markers of neuroinflammation and neurodegeneration facilitates patient selection and treatment monitoring.

Key Points: 
  • In addition, their proprietary exosome-based diagnostic that detects and quantifies markers of neuroinflammation and neurodegeneration facilitates patient selection and treatment monitoring.
  • BIORCHESTRA has been recently recognized for its achievements by Johnson & Johnson in their Innovation QuickFire Challenge in Neuroscience in June, 2021.
  • [i][ii]
    Reflecting the success of its research and development programs and anticipating its international expansion and entry into clinical development, the BIORCHESTRA has appointed Dr. Louis St.L.
  • O'Dea (MB, BCh, BAO, FRCP has worked as CMO in global pharmaceutical companies such as Serono, Moderna, Akcea (Ionis), Radius and Oxford Immunotec for 28 years.

ICBII Announces Approval of Its 7th Patent on Blood-Brain Barrier Permeable Technology, Moving Closer to Clinical Trials on its drugs for Alzheimer's, Parkinson's, and Other Neuro-Degenerative Diseases

Thursday, September 23, 2021 - 1:26am

LA JOLLA, Calif., Sept. 22, 2021 /PRNewswire/ -- Innovative California Biosciences International, Inc., ("ICBII"), has announced the approval of its 7th patent for Blood-Brain Barrier (BBB) Permeable Peptide Compositions.

Key Points: 
  • LA JOLLA, Calif., Sept. 22, 2021 /PRNewswire/ -- Innovative California Biosciences International, Inc., ("ICBII"), has announced the approval of its 7th patent for Blood-Brain Barrier (BBB) Permeable Peptide Compositions.
  • Approval of this patent further strengthens Company's IP portfolio of its SMART* Molecules technology and brings the management closer to the clinical trials.
  • ICBII's SMART molecules technology is blazing the path to non-invasively diagnosis and potentially curing brain diseases by delivering drugs to targeted sites that has not been possible so far.
  • The drugs that do cross the blood brain barrier only provide short-term symptomatic relief without altering disease progression.

Alpha Cognition Announces Overnight Marketed Offering

Wednesday, September 22, 2021 - 10:08pm

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce it has commenced an overnight marketed public offering (the “Offering”) of units (the “Units”) of the Company.

Key Points: 
  • NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES
    VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (Alpha or the Company) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce it has commenced an overnight marketed public offering (the Offering) of units (the Units) of the Company.
  • The Offering will be conducted pursuant to the Companys Canadian base shelf prospectus dated August 25, 2021 (the Base Shelf Prospectus).
  • A prospectus supplement (the Prospectus Supplement) relating to the Offering will be filed in each of the provinces of Canada, except the Province of Quebec.
  • Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).

Watercrest Senior Living Offers Seniors Respite Care at Market Street Memory Care Residence East Lake

Wednesday, September 22, 2021 - 6:14pm

VERO BEACH, Fla., Sept. 22, 2021 /PRNewswire/ --Watercrest Senior Living is offering local seniors a short term stay, known as Respite Care, at their Market Street Memory Care Residence East Lake in Tarpon Springs, Fla.

Key Points: 
  • VERO BEACH, Fla., Sept. 22, 2021 /PRNewswire/ --Watercrest Senior Living is offering local seniors a short term stay, known as Respite Care, at their Market Street Memory Care Residence East Lake in Tarpon Springs, Fla.
  • Respite Care is ideal for seniors recovering from a hospital stay, needing care while a caregiver is away, or simply for those individuals wishing to experience firsthand the extraordinary service and amenity-rich environment at Market Street Memory Care Residence East Lake.
  • Owned and operated by Watercrest Senior Living Group, Market Street East Lake is a 64-unit, state-of-the-art memory care community providing world class care, multi-sensory programming, diverse culinary experiences, and unparalleled associate training honoring seniors with Alzheimer's and dementia.
  • Market Street Memory Care Residence East Lake is conveniently located at 833 East Lake Road North in Tarpon Springs.

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

Wednesday, September 22, 2021 - 4:00pm

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBDs superior potency over CBD by factor of 8,000 times.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBDs superior potency over CBD by factor of 8,000 times.
  • Supera-CBD is MyMDs pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration.
  • A vast majority of CBD developers are pursuing compounds targeted to CB2 that have minimal CB1 affinity.
  • Given the remarkable data we are announcing today, we are optimistic that the future opportunity for our synthetic CBD drug candidate is enormous.